About Unlearn.AI
Unlearn AI is a healthcare-focused artificial intelligence company that builds “digital twins” of patients to improve clinical trials. It helps pharmaceutical and biotech companies simulate patient outcomes using AI so they can design faster, smaller, and more efficient clinical studies. The main goal is to reduce trial time, cost, and uncertainty in drug development by predicting patient health outcomes more accurately.
Feature Highlights
Unlearn AI creates digital twins of clinical trial participants using historical medical data and machine learning models to predict future health outcomes more efficiently.
It provides a trial design and analysis platform that helps researchers plan studies, simulate scenarios, and improve statistical confidence before launching trials.
It supports “external control arms,” allowing smaller patient groups by simulating what would have happened without treatment.
The system improves decision-making in early-stage drug development by showing expected results earlier in the research process.
It integrates with real-world clinical and research datasets to validate assumptions like patient response, endpoints, and feasibility.
It is designed to be compliant with regulatory guidance (FDA/EMA aligned methodologies) for clinical trial use.
Use Cases
Designing and optimizing clinical trials for pharmaceutical companies
Reducing the number of patients needed in control groups
Speeding up drug development in diseases like Alzheimer’s, oncology, and metabolic disorders
Testing trial outcomes before actual patient enrollment
Improving statistical power and reliability of medical studies
Helping biotech companies make faster go/no-go decisions
Simulating future patient outcomes to compare multiple treatment strategies before trials begin
Using AI-generated patient models to explore “what-if” medical scenarios
Supporting regulatory submissions with AI-backed trial evidence and simulations